We showed that significantly more pathogenic mutations from TP53, BRCA2, and RECQL4 occurred in patients with ESCC than in control cohorts, which indicates that these three CSGs may play vital roles in ESCC. The gene discussed is BRCA2; the disease is esophageal squamous cell carcinoma.